Daggerwing Health Pharmaceuticals is collaborating with researchers and key opinion leaders at international centers of excellence to leverage multi-disciplinary expertise in drug delivery, formulation, and development. Our research collaborations provide DHP with the optimal platform on which to pursue the development of new therapies for neurodegenerative, autoimmune, and other diseases.

The Complutense University of Madrid is a public research university located in Madrid, and one of the oldest universities in the world. DHP-102 has been evaluated in preclinical models of Parkinson´s disease and amyotrophic lateral sclerosis (ALS) in collaboration with Prof. Javier Fernandez-Ruiz, a full Professor of Biochemistry and Molecular Biology at the University Complutense of Madrid (Spain). The results of these studies have been published in the Journal of Neuroinflammation (2018), Molecules (2019), Biochemical Pharmacology (2018) and Scientific Reports (2016).

The proneurogenic activity of DHP-102 on neuronal stem cells has been demonstrated in preclinical models of Huntington’s disease (HD) in collaboration with Dr. Ismael Galve-Roperh, an Associate Professor of Biochemistry and Molecular Biology at the University Complutense of Madrid (Spain). The results in the HD model have been published in Scientific Reports (2016) and Translational Neurodegeneration (2019)

The Cajal Institute (IC) is a research center in neurobiology, which belongs to the Spanish National Research Council (CSIC). DHP-101 has been evaluated in preclinical models of multiple sclerosis (MS), such as the experimental autoimmune encephalomyelitis (EAE) and the Theiler’s virus-induced encephalopathy (TMEV) murine models, in collaboration with Dr. Carmen Guaza, a full Professor at the Cajal Institute, Spanish National Research Council (Madrid, Spain). The data on the hypoxia mimetic activity of DHP-101 have been reported in the Journal of Neuroinflammation (2018).

The Maimonides Biomedical Research Institute of Cordoba – IMIBIC, is a joint Institute of the University of Cordoba (UCO), the Reina Sofia University Hospital, and the Junta de Andalucía Regional government. IMIBIC brings together scientific research and medical practice to embrace integral projects with the ultimate aim to promote a much faster and efficient communication between clinical and preclinical research, and to generate knowledge of high impact with considerable potential of translation into practice, new therapies and innovative products.

VCE-004.8 has been evaluated in a preclinical model of metabolic syndrome induced by high fat diet in collaboration with Dr. Manuel Tena-Sempere, a full Professor of Physiology at the University of Córdoba (IMIBIC). The data on the anti-obesity activity of VCE-004.8 have been reported in the Scientific Reports (2018). In addition, a collaboration is ongoing with the proteomic unit and Prof. Eduardo Muñoz at the IMBIC to analyze plasmatic drug-related biomarkers.